The following represents disclosure information provided by authors of this abstract. The program committee has reviewed all presenting author disclosure reports, identified potential conflicts of interest, and implemented strategies to manage those areas of conflict, where appropriate. All relationships are considered compensated. Relationships are self-held unless otherwise noted. I = Immediate Family Member, Inst = My Institution
 
Open Payments is a public database containing information reported by companies about payments made to US-licensed physicians (Open Payments)
ARC-9: A randomized study to evaluate etrumadenant based treatment combinations in previously treated metastatic colorectal cancer (mCRC).
 
Zev A. Wainberg
Consulting or Advisory Role - Alligator Bioscience; Amgen; Arcus Biosciences; Astellas Pharma; AstraZeneca/MedImmune; Bayer; Bristol-Myers Squibb; Daiichi Sankyo/Astra Zeneca; Ipsen; Lilly; Merck; Merck KGaA; Novartis; Pfizer; PureTech; Seagen
Research Funding - Five Prime Therapeutics (Inst); Merck (Inst); Novartis (Inst); Pfizer (Inst); Plexxikon (Inst)
Travel, Accommodations, Expenses - Amgen; Bayer; Lilly; Merck
 
Sae-Won Han
Honoraria - IMBdx
Research Funding - Arcus Biosciences (Inst); BeyondBio (Inst); GC Pharma (Inst); Genentech (Inst); Hanmi (Inst); Hengrui Pharmaceutical (Inst); IMBdx (Inst); Janssen (Inst); Jeil Pharmaceutical Co (Inst); Lilly (Inst); Loxo (Inst); MedImmune (Inst); Mirati Therapeutics (Inst); MSD (Inst); Roche (Inst); Seagen (Inst); Turnstone Bio (Inst)
 
Soohyeon Lee
Stock and Other Ownership Interests - Celgene/Bristol-Myers Squibb; Pfizer
Consulting or Advisory Role - PharmAbcine
Research Funding - Jeil Pharmaceutical Co
Travel, Accommodations, Expenses - ST Cube
 
Keun-Wook Lee
Honoraria - Astellas Pharma; Bayer; Daiichi Sankyo; JW Pharmaceutical; Merck KGaA; Sanofi/Aventis
Consulting or Advisory Role - Astellas Pharma; Daiichi Sankyo; Metafines; MSD
Research Funding - ALX Oncology (Inst); Amgen (Inst); Arcus Biosciences (Inst); Astellas Pharma (Inst); AstraZeneca/MedImmune (Inst); BeiGene (Inst); Bolt Biotherapeutics (Inst); Daiichi Sankyo (Inst); Elevar Therapeutics (Inst); Genome & Company (Inst); Ildong Pharmaceutical (Inst); InventisBio (Inst); Leap Therapeutics (Inst); Macrogenics (Inst); MedPacto (Inst); Merck KGaA (Inst); MSD (Inst); Ono Pharmaceutical (Inst); Roche (Inst); Seagen (Inst); Taiho Pharmaceutical (Inst); Trishula Therapeutics (Inst); Y-BIOLOGICS (Inst); Zymeworks (Inst)
(OPTIONAL) Uncompensated Relationships - ALX Oncology
 
Scott Kopetz
Stock and Other Ownership Interests - Frontier Medicines; Iylon; Lutris; Navire; Xilis
Consulting or Advisory Role - Abbvie; Accademia Nazionale Di Medicina (ACCMED); Amal Therapeutics; Amgen; AstraZeneca/MedImmune; AVEO; Bayer Health; Bicara Therapeutics; Black Diamond Therapeutics; Boehringer Ingelheim; Bristol-Myers Squibb/Medarex; Cardiff Oncology; Carina Biotech; CureTeq; EMD Serono; Endeavor BioMedicines; Flame Biosciences; Foundation Medicine; Frontier Medicines; Genentech; Genomic Health; Gilead Sciences; GlaxoSmithKline; HalioDx; Harbinger Oncology, Inc; Holy Stone Healthcare; Inivata; Ipsen; Iylon; Jacobio; Jazz Pharmaceuticals; Johnson & Johnson/Janssen; Lilly; Lutris; Merck; Mirati Therapeutics; NeoGenomics Laboratories; Novartis; Numab; Ono Pharmaceutical; Pfizer; Redx Pharma; Repare Therapeutics; Replimune; Roche; Sanofi; Servier; Tachyon Therapeutics; Taiho Pharmaceutical; Takeda; Tempus; Xilis; Zentalis
Research Funding - Amgen; Array BioPharma; Biocartis; Daiichi Sankyo; EMD Serono; Genentech/Roche; Guardant Health; Lilly; MedImmune; Novartis; Sanofi
 
Jonathan Mizrahi
Honoraria - AstraZeneca; Exelixis
Consulting or Advisory Role - Amgen; Daichii Sankyo; Exelixis; Seagen
Speakers' Bureau - AstraZeneca; Bristol Myers Squibb Foundation; Exelixis
 
Yong Sang Hong
No Relationships to Disclose
 
François Ghiringhelli
Honoraria - roche
Research Funding - AstraZeneca/MedImmune (Inst)
Travel, Accommodations, Expenses - Amgen; Amgen; Amgen; Roche/Genentech; Roche/Genentech
 
Antoine Italiano
Honoraria - Bayer; Daiichi Sankyo; Epizyme; IPSEN; Lilly; Novartis; Roche
Consulting or Advisory Role - Bayer; Daiichi Sankyo; Epizyme; Immune Design; Lilly; Roche
Research Funding - AstraZeneca/MedImmune; Bayer; Merck Serono; Merck Serono; MSD Oncology; PharmaMar; Roche
Patents, Royalties, Other Intellectual Property - BMS
 
David Tougeron
Honoraria - Amgen; AstraZeneca; Bristol-Myers Squibb; Bristol-Myers Squibb; Merck Serono; MSD; Pierre Fabre; Roche; Sanofi; Servier/Pfizer; Takeda
Consulting or Advisory Role - AstraZeneca; BMS; MSD; Novartis; Pierre Fabre; Sanofi; SERVIER; Takeda
Research Funding - BTG (Inst); MSD (Inst); Pierre Fabre (Inst); Roche (Inst); Takeda (Inst)
Travel, Accommodations, Expenses - Amgen; Bristol-Myers Squibb; MSD Oncology; Pierre Fabre; Roche; SERVIER
 
Brandon Beagle
Employment - Arcus Biosciences
Stock and Other Ownership Interests - BeiGene
Travel, Accommodations, Expenses - BeiGene
 
Mathew Boakye
Employment - Arcus Biosciences
Stock and Other Ownership Interests - Arcus Biosciences
 
Tingting Zhao
Employment - Arcus Biosciences
Stock and Other Ownership Interests - Arcus Biosciences; Erasca, Inc
 
Joon Rhee
Employment - Gilead Sciences
Stock and Other Ownership Interests - Gilead Sciences
Travel, Accommodations, Expenses - Gilead Sciences
 
Dimitry S. A. Nuyten
Employment - Arcus Biosciences; Nektar; Olema Pharmaceuticals (I)
Leadership - Arcus Biosciences; Nektar; Olema Pharmaceuticals (I)
Stock and Other Ownership Interests - Abbott Laboratories; Allogene Therapeutics; Amgen; Arcus Biosciences; AstraZeneca; BeiGene; Biomarin; Blackstone; Bristol-Myers Squibb/Celgene; Chinook Therapeutics; CVS Health; Genmab; HCA Healthcare; Illumina; Kezar Life Sciences; Merck; Merck; Metlife Insurance; Mirati Therapeutics; Moderna Therapeutics; Nektar; Novo Nordisk; Pfizer; Radius Health; Regeneron; Sangamo Therapeutics; Seagen; Synlogic; Synlogic; Teva; Turning Point Therapeutics (I); United Health Group; Veeva Systems; Viatris
Patents, Royalties, Other Intellectual Property - My spouse was VP of development and with that shareholder of Peloton Therapeutics. Merck's acquisition cam with milestone payments based on commercial milestones for belzutifan (Welireg). With that we anticipate to receive (consider similar to royalty) fu (I); See https://patents.justia.com/inventor/dimitry-serge-antoine-nuyten
Travel, Accommodations, Expenses - Arcus Biosciences
 
Michael Cecchini
Stock and Other Ownership Interests - Parthenon Therapeutics
Honoraria - Agenus; AstraZeneca; Bayer; Daiichi Sankyo/Astra Zeneca; DAVA Pharmaceuticals; Elevation Oncology; Incendia Therapeutics; Loxo/Lilly; Macrogenics; Regeneron; Seagen; Taiho Oncology